Takeda Pharmaceutical Company Limited (NYSE:TAK - Get Free Report)'s share price hit a new 52-week low during trading on Monday . The stock traded as low as $13.19 and last traded at $13.20, with a volume of 1302449 shares. The stock had previously closed at $13.37.
Takeda Pharmaceutical Trading Down 1.4 %
The company has a quick ratio of 0.55, a current ratio of 1.06 and a debt-to-equity ratio of 0.64. The firm's 50-day simple moving average is $14.25 and its 200 day simple moving average is $14.30. The stock has a market capitalization of $41.73 billion, a P/E ratio of 19.98, a PEG ratio of 3.78 and a beta of 0.53.
Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last issued its quarterly earnings results on Thursday, February 1st. The company reported $0.51 EPS for the quarter. Takeda Pharmaceutical had a net margin of 6.90% and a return on equity of 12.57%. The firm had revenue of $7.52 billion for the quarter. Equities research analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.5 EPS for the current fiscal year.
Insider Activity
In related news, major shareholder Pharmaceutical Co Ltd Takeda sold 3,703,703 shares of the firm's stock in a transaction that occurred on Wednesday, January 24th. The shares were sold at an average price of $8.10, for a total value of $29,999,994.30. Following the completion of the transaction, the insider now owns 3,755,583 shares of the company's stock, valued at approximately $30,420,222.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.04% of the stock is owned by company insiders.
Institutional Investors Weigh In On Takeda Pharmaceutical
Several hedge funds have recently bought and sold shares of TAK. Rise Advisors LLC purchased a new stake in shares of Takeda Pharmaceutical in the first quarter worth approximately $26,000. Harbour Investments Inc. lifted its position in Takeda Pharmaceutical by 282.9% in the 2nd quarter. Harbour Investments Inc. now owns 1,639 shares of the company's stock worth $26,000 after buying an additional 1,211 shares in the last quarter. GAMMA Investing LLC acquired a new stake in shares of Takeda Pharmaceutical during the 4th quarter valued at $28,000. Principal Securities Inc. purchased a new position in shares of Takeda Pharmaceutical during the 4th quarter valued at $28,000. Finally, First United Bank & Trust acquired a new position in shares of Takeda Pharmaceutical in the fourth quarter worth $29,000. 9.17% of the stock is owned by hedge funds and other institutional investors.
About Takeda Pharmaceutical
(
Get Free Report)
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.
Recommended Stories
Before you consider Takeda Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Takeda Pharmaceutical wasn't on the list.
While Takeda Pharmaceutical currently has a "hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
